Home / Products / Inhibitors / AKT Inhibitors / 1032350-13-2


Cat.No.ABP000407 Chemical NameMK-2206/MK2206 MolFormulaC25H23Cl2N5O MolWeight480.389 Purity 99%

Chemical Name : MK-2206/MK2206

CAS : 1032350-13-2

Synonyms: 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride


Storage:Storage at -20C 2 years


MK-2206, a highly selective non-ATP competitive allosteric Akti, has nM IC50 and broad preclinical antitumor activity.MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. 1 hr treatment of 1 µM MK-2206 abolished Akt phosphorylation in U87MG cells. MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MG cells.MK-2206 is generally well tolerated at doses up to 60 mg QOD with plasma concentrations that portend activity in preclinical models. PK/PD data suggest a substantial and maintained target inhibition at 60 mg.


1. Hui-Fang Li , Jung-Sik Kim , Todd Waldman. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells Radiation Oncology 2009, 4:43 2. A. W. Tolcher . A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). Meeting: 2009 ASCO Annual Meeting